Tolvaptan
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Tolvaptan
- Tolvaptan: From Undocumented Original Indication to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
Tolvaptan: From Undocumented Original Indication to Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease)
One-Sentence Summary
Tolvaptan (DrugBank DB06212) is a vasopressin V2-receptor antagonist; its original approved indication is not recorded in the available regulatory data for this evidence pack. The TxGNN model predicts it may be effective for Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease), i.e., autosomal dominant polycystic kidney disease (ADPKD), a prediction strongly reinforced by two completed Phase 3 RCTs and multiple systematic reviews/consensus statements already establishing tolvaptan's clinical role in this exact disease area.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no Taiwan/NZ license records or original_indications data on file |
| Predicted New Indication | Polycystic Kidney Disease 3 (with or without Polycystic Liver Disease) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, the drug-level mechanism of action field is a data gap. However, evidence embedded in the prediction record indicates tolvaptan is a vasopressin V2-receptor antagonist: it blocks V2 receptor–mediated cAMP signaling in renal tubular epithelium, a pathway that directly drives cyst epithelial proliferation and fluid secretion in polycystic kidney disease.
The predicted indication — "polycystic kidney disease 3" — falls within the autosomal dominant polycystic kidney disease (ADPKD) family (PKD1/PKD2/PKD3 genotypes), for which the V2-receptor/cAMP cystogenesis pathway is an already-validated drug target. This gives the TxGNN prediction strong mechanistic plausibility rather than a purely associative signal.
It is worth flagging a data-quality note directly from the evidence pack's own analysis: the record shows market_status = 未上市 (Not Marketed) and original_moa = [Data Gap], which is inconsistent with the substantial Phase 3 RCT and consensus-guideline literature below (tolvaptan/Jynarque is an established, approved ADPKD therapy in multiple jurisdictions). This inconsistency should be manually verified against source registries before final sign-off.
Clinical Trial Evidence
Currently no related clinical trials registered (structured clinical_trials field is empty; the Phase 3 RCT evidence below was captured through literature indexing, not trial-registry evidence).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23121377 | 2012 | RCT (Phase 3, TEMPO 3:4) | The New England Journal of Medicine | Landmark trial: tolvaptan slowed total kidney volume growth and eGFR decline vs. placebo in early ADPKD |
| 29105594 | 2017 | RCT (Phase 3, REPRISE) | The New England Journal of Medicine | Confirmed efficacy/safety of tolvaptan in later-stage ADPKD; noted more frequent aminotransferase and bilirubin elevations |
| 38091246 | 2024 | RCT (pediatric, NCT02964273) | Pediatric Nephrology | Evaluated tolvaptan safety and pharmacodynamics in children (5–17y) with ADPKD |
| 37150675 | 2023 | Systematic Review / Meta-analysis | Nefrologia | Confirmed overall efficacy and safety of tolvaptan for delaying progression to ESRD in ADPKD |
| 39356039 | 2024 | Cochrane Systematic Review | Cochrane Database of Systematic Reviews | Reviewed disease-modifying interventions (including tolvaptan) for preventing ADPKD progression |
| 35134221 | 2022 | Consensus Statement/Review | Nephrology Dialysis Transplantation | ERA/ERKNet/PKD International consensus on tolvaptan use in ADPKD following TEMPO 3:4 |
| 40126492 | 2025 | Review | JAMA | Comprehensive ADPKD overview covering epidemiology and treatment landscape |
| 40726372 | 2025 | Review | Current Opinion in Nephrology and Hypertension | Notes tolvaptan as the only FDA-approved disease-modifying ADPKD therapy; reviews emerging alternatives |
| 35487607 | 2022 | Review | Clinics in Liver Disease | Confirms tolvaptan slows deterioration of renal function and cyst growth in ADPKD/PLD |
| 35328738 | 2022 | Review | International Journal of Molecular Sciences | Reviews ADPKD cystogenesis pathophysiology and treatment advances including tolvaptan |
New Zealand Market Information
Tolvaptan is not currently marketed in New Zealand — no product authorization records are available (total_licenses = 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed Phase 3 RCTs (TEMPO 3:4, REPRISE) plus a Cochrane systematic review and an international consensus statement meet the L1 evidence bar for efficacy in ADPKD. However, regulatory safety data (MOA, package-insert warnings, contraindications, DDI) are all flagged as data gaps — one marked Blocking — so the candidate cannot yet clear the S1 safety pre-screen despite strong efficacy evidence.
To proceed, the following is needed:
- TFDA/NZ package insert warnings and contraindications (Blocking data gap DG001)
- Confirmed mechanism of action from DrugBank (High-priority data gap DG002)
- Verification of the market_status inconsistency (record shows "Not Marketed" despite established global ADPKD approval)
- Liver function monitoring plan — REPRISE trial data show increased aminotransferase/bilirubin elevations with tolvaptan use
- New Zealand/Taiwan regulatory license status confirmation before any market-entry planning
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.